Vanda Pharmaceuticals | VNDA - Equity Capital And Reserves


Vanda Pharmaceuticals reported $327.19M in Equity Capital and Reserves for its fiscal quarter ending in December of 2025.





Equity Capital And Reserves Change Date
Acadia Pharmaceuticals USD 917.27M 94.89M Sep/2025
Agios Pharmaceuticals USD 1.19B 91.22M Dec/2025
Akebia Therapeutics USD 32.61M 8.98M Dec/2025
Alnylam Pharmaceuticals USD 789.18M 555.28M Dec/2025
Anika Therapeutics USD 146.8M 867K Sep/2025
Arrowhead Research USD 568.42M 102.37M Dec/2025
AstraZeneca USD 48.67B 2.78B Dec/2025
Bristol-Myers Squibb USD 18.55B 1.06B Sep/2025
Eli Lilly USD 26.54B 2.74B Dec/2025
Enanta Pharmaceuticals USD 126.59M 61.87M Dec/2025
Esperion Therapeutics USD -451.36M 17.85M Sep/2025
Halozyme Therapeutics USD 48.81M 455.1M Dec/2025
Heron Therapeutics USD 14.88M 42.14M Sep/2025
Insmed USD 738.98M 206.6M Dec/2025
J&J USD 78.47B 0 Sep/2025
Lexicon Pharmaceuticals USD 129.44M 6.41M Jun/2025
Ligand Pharmaceuticals USD 1.02B 67.04M Dec/2025
Merck USD 51.85B 2.79B Sep/2025
Minerva Neurosciences USD -34.58M 2.47M Sep/2025
Moderna USD 8.65B 680M Dec/2025
Novartis USD 44.33B 2.28B Sep/2025
Pfizer USD 92.8B 4.11B Sep/2025
PTC Therapeutics USD -205.31M 49.56M Dec/2025
Puma Biotechnology USD 115.27M 10.55M Sep/2025
Sangamo BioSciences USD 19.6M 14.7M Jun/2025
Sanofi EUR 71.71B 1.55B Dec/2025
Takeda JPY 7.64T 513.39B Dec/2025
Teva Pharmaceutical Industries USD 7.91B 664M Dec/2025
Ultragenyx Pharmaceutical USD 9.16M 142.13M Sep/2025
Vanda Pharmaceuticals USD 327.19M 138.81M Dec/2025
Veracyte USD 1.26B 36.61M Sep/2025